Genprex (NASDAQ:GNPX – Get Free Report)’s share price shot up 2.1% on Monday . The stock traded as high as $0.5369 and last traded at $0.5050. 270,636 shares were traded during mid-day trading, a decline of 29% from the average session volume of 381,310 shares. The stock had previously closed at $0.4948.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genprex has an average rating of “Sell”.
View Our Latest Stock Analysis on Genprex
Genprex Trading Up 2.1%
Genprex (NASDAQ:GNPX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.
Hedge Funds Weigh In On Genprex
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP grew its position in shares of Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after buying an additional 35,661 shares in the last quarter. Mayflower Financial Advisors LLC purchased a new stake in shares of Genprex during the first quarter worth approximately $36,000. Finally, Manchester Financial Inc. acquired a new stake in Genprex in the first quarter valued at approximately $36,000. Hedge funds and other institutional investors own 14.05% of the company’s stock.
Genprex Company Profile
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
Read More
- Five stocks we like better than Genprex
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
